Background: Alzheimer\u27s disease (AD) is the leading cause of dementia worldwide and affects over 55 million people. Lecanemab and donanemab are anti-amyloid monoclonal antibodies that flag the abnormal amyloid-beta plaques for removal by the immune ...
Khalid, Hassan, Murtada, Mohammed
core
DONANEMAB: A NOVEL THERAPEUTIC APPROACH FOR ALZHEIMER'S DISEASE
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder characterized by memory loss, cognitive impairment, and functional decline, primarily associated with the accumulation of amyloid-β (Aβ) plaques and tau tangles in the brain. Donanemab, a humanized monoclonal antibody, represents a novel therapeutic strategy designed to selectively ...
openaire +1 more source
Donanemab treatment effect by baseline tau burden and disease severity: Observations from the TRAILBLAZER-ALZ 2 trial. [PDF]
Alzheimers DementRaket LL +13 more
europepmc +1 more source
A Narrative Review of Amyloid-β Monoclonal Antibodies for Alzheimer Disease: How Amyloid Species Engagement May Affect Clinical Outcomes. [PDF]
NeurologistCaselli RJ, Geldmacher DS, Schilling TB.
europepmc +1 more source
Cost-Effectiveness of Delaying Alzheimer’s Disease Progression with Novel Monoclonal Antibodies
Thesis (Master's)--University of Washington, 2025Background: In the US alone, most of over 7.2 million older adults with Alzheimer’s Disease (AD) treat their AD with symptom-relieving therapies.
Chung, Minseon Veronica
core
The generalizability gap: anticoagulant exclusions and the "Enhanced Safety" of donanemab in the EU-eligible population. [PDF]
J Prev Alzheimers DisIjaz A, Mohyudin G.
europepmc +1 more source
Amyloid-beta-targeting monoclonal antibodies in early Alzheimer's disease: a cochrane review summary and appraisal for the neurological community. [PDF]
Neurol SciSantos DH, da Silva AMP.
europepmc +1 more source
From Target Engagement to Treatment Governance: The Evolving Role of Amyloid PET in Anti-Amyloid Therapy. [PDF]
Lancet Reg Health EurFilippi M +8 more
europepmc +1 more source
Advancing Theranostics in Alzheimer Disease: FDA Approval of Amyloid-β PET Drugs for Selection of Patients for Amyloid-β-Directed Therapies and Other Labeling Updates. [PDF]
J Nucl MedKoo H +8 more
europepmc +1 more source